ProKidney
ProKidney's lead candidate rilparencel is an autologous cell therapy for chronic kidney disease without immunosuppressive therapy.
- Winston-Salem, NC, USUnited States
ProKidney's lead candidate rilparencel is an autologous cell therapy for chronic kidney disease without immunosuppressive therapy.
What is the investment case, and what must be true for it to hold?
The investment case for ProKidney's rilparencel hinges on Phase 3 confirming kidney-function benefit: REGEN-007 Cohort 1's annual eGFR slope improved from -5.84 before injection to -1.27 after the last injection, a difference of 4.57, while the second cohort's 50% eGFR-slope improvement was not statistically significant.
The Phase 3 accelerated approval efficacy analysis has completed enrollment, with topline results anticipated in Q2 2027. REGEN-006 continues as a Phase 3 trial that is randomized, blinded, and sham-controlled to test rilparencel safety and efficacy in subjects with advanced CKD and type 2 diabetes.
Which risks could break the thesis, and what would warn of them?
ProKidney's investment case rests on Phase 3 confirming the efficacy signal seen in REGEN-007 Cohort 1, because Cohort 2's improvement in eGFR slope was not statistically significant, and the 2027 readout is the key observable test. In Cohort 1, the annual eGFR slope improved from -5.84 before injection to -1.27 after injection, a difference of 4.57. The PROACT 1 accelerated-approval efficacy analysis has completed enrollment, with topline results anticipated in Q2 2027.
ProKidney held $181.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026, down from $224.9 million as of March 31, 2026.
What does the product do for its buyer, and how is it delivered?
Rilparencel is an autologous cell therapy made from a patient's own kidney cells and reinjected into the diseased kidney, intended to preserve kidney function in patients with advanced chronic kidney disease and delivered in the Phase 3 trial by kidney injection.
In the PROACT 1 procedure, delivery is performed percutaneously under conscious sedation as an outpatient same-day procedure, and the Phase 3 trial is being conducted at over 70 clinical sites in the United States, Asia, and Latin America.